AHR and inflammatory bowel disease: It has been proposed that insufficient microbial AHR agonists may contribute to the pathogenesis of IBD, metabolic syndrome, and other conditions (Lamas et al., 2016; Miani et al., 2018; Natividad et al., 2018).